Rosen Law Firm invites ADMA Biologics investors to lead securities fraud class action with August 10 deadline
Executive summary: Rosen Law Firm announced that investors who bought ADMA Biologics (NASDAQ: ADMA) shares between August 9, 2024 and March 25, 2026 may apply to be lead plaintiff in a securities fraud class action, with a deadline of August 10, 2026. The class action alleges false or misleading statements about ADMA’s finances, exposing the company to possible legal expenses, settlement costs, and adverse effects on its stock price and reputation.
Who is involved: Key parties include ADMA Biologics, its shareholders within the defined class period, the Rosen Law Firm as plaintiff’s counsel, and the federal court overseeing the litigation.
Likely next: Shareholders must submit lead plaintiff applications by August 10, 2026; if appointed, the lead plaintiff will direct the litigation, potentially leading to discovery, settlement negotiations, or trial.
The Rosen Law Firm issued a notice inviting ADMA Biologics shareholders who purchased shares between August 9, 2024 and March 25, 2026 to seek lead plaintiff status in a securities fraud class action, citing a filing deadline of August 10, 2026. The lawsuit alleges that the company made false or misleading statements about its financial performance. Such litigation can lead to increased legal costs, potential settlements, and heightened regulatory scrutiny for the firm.
Timeline
- — ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm (PR Newswire)
- — ADMA Biologics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ADMA Biologics, Inc. - ADMA (PR Newswire)
- — INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ADMA Biologics, Inc. of Class Action Lawsuit and Upcoming Deadlines - ADMA (PR Newswire)
- — ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit (PR Newswire)
- — ADMA Biologics (ADMA) Hit With Federal Securities Lawsuit Over Revenue Inflation Allegations (Yahoo Finance)
Analysis — what this means
Likely next events
- ADMA Biologics lead plaintiff filing deadline: August 10, 2026 (per Rosen Law Firm notice)
- GeneDx Holdings (WGS) lead plaintiff filing deadline: August 3, 2026
- Photronics Inc. (PLAB) lead plaintiff filing deadline: August 3, 2026 (per truncated notice)
Sectors affected
- Biologics manufacturing
- Diagnostic testing
- Semiconductor photomask production
Regulatory implications
- Possible SEC enforcement under Rule 10b-5 for alleged misrepresentations
- Risk of disgorgement and civil penalties if fraud is proven
- Increased scrutiny of revenue recognition practices in the biotech sector
Historical parallels
- 2021 Illumina class action over revenue recognition allegations
- 2020 Biogen SEC investigation resulting in a $150 million settlement
- 2018 Celgene securities fraud lawsuit concerning drug pricing disclosures
Key entities
Sources
- ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm — PR Newswire
- ADMA Biologics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ADMA Biologics, Inc. - ADMA — PR Newswire
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ADMA Biologics, Inc. of Class Action Lawsuit and Upcoming Deadlines - ADMA — PR Newswire
- ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit — PR Newswire
- ADMA Biologics (ADMA) Hit With Federal Securities Lawsuit Over Revenue Inflation Allegations — Yahoo Finance
Related cases
- Pomerantz Law Firm files class action against ADMA Biologics, with investor deadline of August 10, 2026, amid repeated securities fraud alerts
- ADMA Biologics faces renewed securities litigation pressure as DJS Law Group reactivates investor outreach for August 2026 class action
- ADMA Biologics faces a looming August 10 deadline for investors to assume lead plaintiff role in a securities fraud class action, highlighting ongoing litigation risk for the biotech firm
- Rosen Law Firm reminds ADMA Biologics investors of the August 10 deadline to serve as lead plaintiff in a securities fraud class action
- ADMA Biologics faces an August 10 deadline for lead plaintiff applications in a securities fraud class action
- ADMA Biologics faces a securities class action alleging violations of federal anti‑fraud statutes, raising legal and investor confidence risks